JNJ-79635322 is under clinical development by Johnson & Johnson and currently in Phase I for Primary Systemic Amyloidosis. According to GlobalData, Phase I drugs for Primary Systemic Amyloidosis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the JNJ-79635322 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JNJ-79635322 is under development for the treatment of relapsed and refractory multiple myeloma and amyloid light-chain amyloidosis (primary systemic amyloidosis). The therapeutic candidate is a tri-specific antibody targeting BCMA, GPRC5D, CD3. It is administered through subcutaneous route.
Johnson & Johnson overview
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular, and metabolic diseases; consumer products in oral care, baby care, beauty, over the counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, neurovascular care, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.
For a complete picture of JNJ-79635322’s drug-specific PTSR and LoA scores, buy the report here.